01167.HK
Jacobio Pharmaceuticals Group Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 6.44
+1.90%Year over year
Reported trailing growth
- Revenue
- +789.2%
- EBITDA
- +152.6%
- EBIT
- +146.2%
- EPS
- +158.5%
- Free cash flow
- +76.1%
- Operating cash flow
- +74.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -18.3%
- EBITDA
- +25.4%
- EBIT
- +12.0%
- Net income
- +8.7%
- EPS
- +10.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026